Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
SKIN Transcript
The Beauty Health Company (SKIN) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call reveals positive developments: increased revenue and EBITDA guidance, successful price hikes, and promising product launches. Although device sales face challenges, consumables show growth, and stabilization efforts are underway. The company's focus on innovation and strategic pricing, coupled with a positive market response to price increases, indicates a potential stock price uplift. However, management's lack of specific guidance for 2026 and ongoing macroeconomic pressures temper expectations, suggesting a moderate positive sentiment.
The Beauty Health Company (SKIN) Q2 2025 Earnings Call Transcript
Unknown8-8
Despite exceeding Q1 revenue and EBITDA guidance, concerns about declining gross margins due to tariffs, increased R&D spending, and macroeconomic pressures, such as higher churn and ASP pressure, neutralize the positive impact. The optimistic guidance and strategic initiatives like new product launches and loyalty programs offer potential upside, but uncertainties in execution and financial health create a balanced outlook.
Earnings call transcript: Beauty Health Co Q1 2025 sees revenue growth, stock dips
Unknown5-8
The earnings call presents a mixed outlook: strong financial metrics with increased revenue and improved EBITDA, but offset by macroeconomic pressures and tariff impacts. The Q&A reveals management's optimism about product launches and market leadership, yet concerns about luxury treatment demand and tariff costs persist. Despite improved gross margins and cash position, uncertainties in China and the global market, along with unclear guidance on tariffs, temper the positive financial results. These mixed factors suggest a neutral stock price movement over the next two weeks.
The Beauty Health Company (NASDAQ:SKIN) Q4 2024 Earnings Call Transcript
Unknown3-13
The earnings call highlights several concerning factors: a projected revenue decline, negative EBITDA guidance, and competitive pressures, particularly in international markets. Despite improvements in consumable sales and gross margin, the challenges in China, economic uncertainties, and lack of clarity on the distributor model raise red flags. The share repurchase program is a positive aspect, but overall, the negative guidance and risks outweigh the positives, suggesting a negative stock price movement.
SKIN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
